RxDoctor Payments Data

Brenda Houdeshell

Nurse Practitioner · Clearfield, PANPI 1487396396

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 54 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$182
  • Novo Nordisk$129
  • Amgen$99
  • Dexcom, Inc.$92
  • Bayer$66
  • Boehringer Ingelheim$62
  • plus $378 from 13 others

What the payments were for

  • Food & beverage$1,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,008 in reported general payments places this provider in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$15,193
Medicare patients
176
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide140$162,531
TrulicityDulaglutide76$107,971
MounjaroTirzepatide75$86,322
JardianceEmpagliflozin59$63,461
Tresiba Flextouch U-100Insulin Degludec105$61,558
FarxigaDapagliflozin Propanediol37$49,210
Tresiba Flextouch U-200Insulin Degludec15$39,948
Humulin R U-500 KwikpenInsulin Regular, Human15$30,638
Victoza 3-PakLiraglutide22$28,262
TradjentaLinagliptin24$19,785
Novolog FlexpenInsulin Aspart67$16,969
Humalog Kwikpen U-100Insulin Lispro66$16,949
Lyumjev Kwikpen U-100Insulin Lispro-Aabc18$14,968
Lantus SolostarInsulin Glargine,hum.Rec.Anlog84$12,399
Repatha SureclickEvolocumab16$11,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$182$197,377164 claims
Novo NordiskOzempic$129$162,531140 claims
Boehringer IngelheimJardiance, Tradjenta$62$83,24683 claims
AstraZenecaFarxiga$19$49,21037 claims
AbbVieSynthroid$44$2,07142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Clearfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →